Meeting
2016 ASCO Annual Meeting
Galeterone in treatment-naïve patients with castration-resistant prostate cancer with C-terminal androgen receptor loss: Results from ARMOR2.
Authors
Mary-Ellen Taplin
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
Mary-Ellen Taplin , Franklin Chu , James S. Cochran , Karen J. Ferrante , David Uri Lipsitz , Jennifer Roberts , Oliver Sartor , Elisabeth I. Heath
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Epidemiology/Outcomes
Clinical Trial Registration Number
NCT01709734
Citation
J Clin Oncol 34, 2016 (suppl; abstr 5064)
DOI
10.1200/JCO.2016.34.15_suppl.5064
Abstract #
5064
Poster Bd #
321
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Randomized, open-label, multicenter, controlled study of galeterone vs enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC) expressing AR-V7 splice variant (ARMOR3-SV).
First Author: Emmanuel S. Antonarakis
Poster
2014 Genitourinary Cancers Symposium
In vitro reproduction and explanation of an abiraterone acetate withdrawal phenomenon.
First Author: Paul Thelen
Poster
2019 ASCO Annual Meeting
Targeting IGF-1/2 with xentuzumab (Xe) plus enzalutamide (En) in metastatic castration-resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy (DCt) and abiraterone (Abi): Randomized phase II trial results.
First Author: Syed A. Hussain
Poster
2015 Genitourinary Cancers Symposium
Initial results from a phase II study of increased-dose abiraterone acetate in patients with castration resistant prostate cancer (CRPC).
First Author: Terence W. Friedlander